The method is non-invasive wrinkle removal and skin rejuvenation

 

(57) Abstract:

The invention relates to medicine and can be used in plastic surgery and dermatology. Affect the skin by radiation of a pulsed laser with a wavelength of 511 or 578 nm, the collagen layer under the epidermis to a depth of 1-1 .2 mm, the duration of the laser pulses of 10-50 NS, a repetition rate of 10-30 kHz. The exposition of the train of laser pulses with a total duration of about 0.1 to 0.3 seconds in the spot on the skin containing wrinkles, 0,2-2,0 mm, the power Density does not exceed 10 j/cm2. The number of procedures and the interval between them is set depending on the depth and number of wrinkles and the size of the skin area. The method allows to remove wrinkles, folds, scars without the risk of postoperative complications and injuries treated surface of the skin. 2 C.p. f-crystals.

The invention relates to the field of plastic surgery and dermatology, more precisely to the field of skin rejuvenation, removal of wrinkles, folds and scars.

Over the past few years, a number of techniques, can significantly rejuvenate aging skin. This laser skin resurfacing, chemical peels, Botox injections and collagen. These and other, less common in our country methods, Nicolina ease of use and short-lived effect (2-6 months), or long, up to two hours of surgery with anesthesia, a long recovery period and possible complications, resulting in a very noticeable improvement in appearance, which can persist for several years. Historically effect on facial wrinkles were performed initially using peels or dermoabrasion. Using a chemical peel requires high qualification of the doctor, as it is difficult to accurately monitor and predict the depth of tissue damage after such peeling is applied. Deep chemical peels are, in particular, a high risk of hyperpigmentation and scarring. Such damage to the top layer of skin to be removed during a chemical peel, allows new cells to rejuvenate the skin. Less expensive way to rejuvenate the outer layer of the skin is the use of abrasive technology, califomia skin layer. This method is poorly controlled and very difficult to use, for example, about the eye lids.

Laser skin rejuvenation has begun using a carbon dioxide laser. Energy CO2laser is absorbed by water contained in the tissue, causing vaporization of the outer layer of the skin. CO2the laser was used on pretreament to remove thin layers of skin with minimal heat damage to the surrounding tissue. While CO2laser can remove about 150 microns of the skin, the skin after such exposure may require a month or more to heal [1].

Er: YAG laser was used for ablation even more thin layers of skin than CO2-laser. However, this laser has no coagulation properties and therefore causes more bleeding during the procedure than CO2laser [2].

Non-ablative skin rejuvenation (for example, pulsed light sources) is a method that does not affect the top layer of the skin, but which shrinks the collagen under the skin and modifies the collagen so that wrinkled skin looked as if filled with collagen, modified under the skin surface. This methodology, however, has a low efficiency and requires, for example, to cool the skin surface, spraying a cryogenic cooler to minimize damage to the top layers of the skin, and to minimize pain. The energy density for this procedure more than 10 joules per square cm, and to make the procedure more effective, often use an energy density of 30 j per square see This level of energy density often causes pain and damage to the epidermis.

Most wrinkles and rejuvenate the skin, described in U.S. patent No. 6077294 (IPC7A 61 N 5/00) (prototype) [3].

In August 2000, the method has been approved by FDA (Food and Drug Asssotiation) for use in the United States to remove wrinkles around the eyes. For the procedure uses a pulsed dye laser, long known in the cosmetic surgery as "vascular laser. Wavelength from 570 to 650 nm (preferably 585 nm), pulse duration 150-1500 μs (preferably 350 μs), the energy density in the treatment of up to 5.0 j/sq. see the Laser approved by the FDA for wrinkle smoothing, called NLite. Since August of last year after the method of laser wrinkle smoothing was introduced in the United States, on the NLite laser started to work 500 doctors, and was performed more than 35,000 procedures. The first patients participating in the study, the procedure was performed about two years ago. It is now clear that the method for smoothing wrinkles vascular laser NLite gives lasting, persisting for at least 2 years.

Method of influence on the human skin, which stimulates the growth of collagen in the layer under the epidermis, consists in the following.

The light pulses generated by the laser into the tissue, affecting the hemoglobin in the collagen layer to a depth of up to 1.2 mitot method has significant drawbacks. The minimum spot size, which focuses the laser beam is 10 mm in diameter, which is considerably greater than the width of wrinkles. This mismatch between the size of the irradiated area of skin the size of the skin defect leads to overexposure surrounding the wrinkle the skin, causing unwanted side effects and complications such as Hypo - and hyperpigmentation, and so on, in Addition, powerful single pulse dye laser (duration about 450 μs) often leads to the rupture of blood vessels due to boiling of the liquid inside the vessel.

The present invention is the creation of an effective non-invasive method of skin rejuvenation, wrinkle removal, wrinkles, scars using a pulsed laser stimulating collagen layer of the skin, without the risk of postoperative complications and injuries treated surface of the skin.

The problem is solved as follows. Proposed removal of wrinkles, folds, scars, and rejuvenate the skin to affect the skin by radiation of a pulsed laser with a wavelength of 570-650 nm, stimulating the growth of collagen under the skin's surface at a depth of 1-1 .2 mm, whereas the pulsed laser is proposed to use a pulsed laser vapor m copper with a wavelength of 511 or 578 nm, duration laser pulses of 10-50 NS, repetition rate of 10-30 kHz and irradiation of collagen to a depth of 1-1,2 mm under the skin surface to carry out a train of laser pulses (total number several thousands) duration of 0.05-0.3 sec.

When laser radiation is focused into a spot on the skin with a size of 0.2-2 mm (preferably about 0.6 mm), and the power density range is not to exceed 10 j/sq cm, which corresponds to the average radiation power of 0.1-0.8 wt. The time of the procedure - about 20 minutes - depends on the size of the treated skin and wrinkles. During the procedure, the injured skin does not occur, the patient is not experiencing pain, anesthesia is not required. After the procedure, no trace on the skin. Special care is not required, complications do not arise. Immediately after the procedure the patient can return to work or to engage in any of its Affairs, except for strenuous exercise. In the dermal layer of the skin after the procedure begins intensively to produce new collagen, which subsequently replaces the lost skin collagen. The result is wrinkles begin to gradually decrease. Improved appearance for the first time will be noticeable in nine decrease on average, 65%. Re-treatments in 14-28 days after the first increases the final effect.

The number of procedures and the interval between them are determined depending on the depth of wrinkles and the size of the treated skin area.

In addition, delivery and focusing of the pulses of the copper vapor laser is proposed to carry out a fiber with a specially designed nozzle.

The design of the nozzles used two variants

1. Focusing the lens on the surface of the skin. The lens system constructs an image of the end of the fiber on the surface of the skin. This wrinkle traced by a light spot corresponding to the optical magnification of the system and the size of the fiber used for the transportation of radiation.

2. The nozzle is a specially processed fiber end, while during the procedure, the tip is performed by a wrinkle in contact while pressing higher penetration of light in tissue. This option provides the ease of use, and, most importantly, provides the best clinical results.

The nozzle is located opposite the skin with wrinkles and focuses the laser emission the skin, without damaging the surrounding tissue. The copper vapor laser generates pulses of light with a wavelength of 511 and 578 nm, pulse duration of 10 to 50 NS with a repetition frequency of 10-30 kHz. Is exposure of the skin train such laser pulses with a total duration of 0.05 to 0.3 seconds, which penetrate to a depth of 1.0-1.2 mm below the surface of the skin, affecting the growth of collagen.

While the use of laser dyes leads to rupture of blood vessels due to boiling of the liquid inside the vessel, the copper vapor laser, on the contrary, compresses the vessels due to the large number of pulses with a high peak power in Zug pulses (usually several thousand pulses), each of which carries a small energy. But due to the accumulation of energy the total energy input to the vessel train of pulses is sufficient for coagulation [4].

The size of the light spot, which focuses the radiation (0.2 to 2.0 mm), proposed in the present invention, is defined as the characteristic size of the wrinkles or mesh of wrinkles and helps to avoid overexposure surrounding the wrinkle of the skin. It is the laser, metal vapor provides high quality optical radiation, which makes possible its focus to the small size is especial heating the collagen under the skin surface by a specified amount and not to cause burns on the skin surface. Moreover, the magnitude of the heating vessels should not exceed 10-30C to avoid microscope liquid in the vessels, on the one hand, and, on the other hand, to be sufficient for coagulation.

The repetition rate of metal vapor lasers is typical of this class of lasers in which these lasers provide the maximum power output and efficiency.

Examples of the method

Patient M., 43 years of age, was treated with laser installation on copper vapor, the wavelength of 578 nm, smoothing eye wrinkles. Each wrinkle was traceroutes spot size of 0.6 mm, the average power of 0.4-0.5 W, the duration of exposure in each spot of 0.1 sec. Took 4 courses of treatment with an interval of 2 weeks each. Wrinkles completely subsided.

Patient K., 51, underwent treatment laser copper vapor, the wavelength of 578 nm, wrinkles on the forehead. Each wrinkle was traceroutes spot size of 0.6 mm, the average power of 0.5 W, the duration of exposure in each spot of 0.2 sec. Received 2 courses of treatment with an interval of 2 weeks each. Wrinkles were smoothed by more than 50%.

Patients who would like to improve their appearance with the help of laser slivovic the rejuvenation. In some cases, for deeper wrinkles were obtained better results than for smaller ones. Many patients like the fact that the results appear gradually, as they do not want others to know that they were cosmetic treatment. Since the procedure is selective and sparing the epidermis, it can be applied to all skin types, even the usually problematic for laser surgery for dark skin. Smuglokozhie patients do not need to prepare for the procedure by using bleaching creams, as this must be done before CO2-laser resurfacing. The risk of hyperpigmentation is almost absent.

Patients-men like this treatment because of the gradual manifestation of the results to older patients like that does not need the use of anesthesia. It is also possible to repeat the procedure. In order to improve the final result, the treatment can be carried out two or three times. Thus, a painless, leaves no traces, not requiring long and complex care method of reducing wrinkles. In this way freed from wrinkles 35 patients. Although the full results to the 90-th day, patients see improvement after 6 weeks. After the escolca weeks gradually in the skin will begin to form new collagen. He begins to fill in wrinkles, and they become smaller. As a result the skin looks young and smooth.

Literature

1. Tanzi EL, Alster TS. Single-pass carbon dioxide versus multiple-pass Er: YAG laser skin resurfacing: a comparison of postoperative wound healing and side-effect rates. Dermatol Surg. 2003 Jan; 29(1): 80-4.

2. Tanzi EL, Alster TS. Side effects and complications of variable-pulsed erbium:yttrium-aluminum-garnet laser skin resurfacing: extended experience with 50 patients. Plast Reconstr Surg. 2003 Apr; 111(4): 1524-9.

3. U.S. patent No. 6077294 IPC7A 61 N 5/00.

4. O. T. Tan, T. J. Stafford, S. Murray, A. K. Kurban Histologic Comparison of the Pulsed Dye Laser and Copper Vapor Laser Effects on Pig Skin.

1. The method is non-invasive wrinkle removal and skin rejuvenation, including the effects of pulsed laser radiation on collagen layer under the epidermis to a depth of 1-1 .2 mm, characterized in that the exposure is performed by the radiation of the copper vapor laser at a wavelength of 511 nm and/or 578 nm with a duration of laser pulses of 10-50 NS, repetition rate of 10-30 kHz and exposition of the world such laser pulses with a total duration of about 0.1-0.3 s in the spot on the skin containing wrinkles, 0,2-2,0 mm at a power density not to exceed 10 j/cm2while the number of procedures and the interval between them is set depending on the depth and number of wrinkles and the size of the skin area.

2. With syshestvyut the light guide with focusing attachment.

3. The method according to p. 1, characterized in that impinges on the light spot size of 0.6 mm

 

Same patents:

The invention relates to medicine, namely to gynecology

The invention relates to medicine, namely to gastroenterology

The invention relates to medicine, namely to gastroenterology

The invention relates to medicine and can be used in the treatment of purulent-inflammatory processes in soft tissues and internal organs and allows you to accelerate the phase change of wound healing and healing and to achieve more pronounced cosmetic effect

The invention relates to medical equipment and can be used for correction of functional disorders of man

The invention relates to medicine, namely to Phthisiology

The invention relates to medicine, namely to pulmonology and physiotherapy
The invention relates to medicine, namely to reducing treatment in traumatology and orthopedics, and can be used in patients with arthrosis, osteochondrosis of the spine, herniated intervertebral disc, epicondylitis, bruises, syndrome title, carpal tunnel, etc

The invention relates to medicine, gynecology

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-0.3 ml of photosensitizing gel preliminarily activated with laser radiation, after having removed neovascular membrane. The photosensitizing gel is based on a viscoelastic of hyaluronic acid containing khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-2% by mass. The photosensitizing gel is in vitro activated with laser radiation having wavelength of 661-666 nm during 3-10 min with total radiation dose being equal to 100-600 J/cm2. The gel is introduced immediately after being activated. To compress the retina, vitreous cavity is filled with perfluororganic compound or air to be further substituted with silicon oil. The operation is ended with placing sutures on sclerotomy and conjunctiva areas. Compounds like chealon, viscoate or hyatulon are used as viscoelastic based on hyaluronic acid. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity.

EFFECT: excluded recurrences of surgically removed neovascular membrane and development of proliferative retinopathy and retina detachment; retained vision function.

3 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: method involves making incision in conjunctiva and Tenon's capsule of 3-4 mm in size in choroid hemangioma projection to sclera 3-4 mm far from limb. Tunnel is built between sclera and Tenon's capsule to extrasclerally introduce flexible polymer magnetolaser implant through the tunnel to the place, the choroid hemangioma is localized, after performing transscleral diaphanoscopic adjustment of choroid hemangioma localization and size, under visual control using guidance beam. The implant has permanent ring-shaped magnet in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 2-3 mTesla units intensity. It is arranged with its north pole turned towards the choroid hemangioma so that extrascleral implant laser radiator disposition. The other end of the implant is sutured to sclera 5-6 mm far from the limb with two interrupted sutures through prefabricated openings. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. 0.1-1% khlorin solution is injected in intravenous bolus dose of 0.8-1.1 mg/kg as photosensitizer and visual control of choroid hemangioma cells fluorescence and fluorescent diagnosis methods are applied. After saturating choroid hemangioma with the photosensitizer to maximum level, transscleral choroid hemangioma laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm with total radiation dose being equal to 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the intraocular neoplasm, repeated laser irradiation of the choroid hemangioma is carried out with radiation dose of 30-60 J/cm2.

EFFECT: enhanced effectiveness of treatment.

4 cl

FIELD: medicine.

SUBSTANCE: method involves creating tunnel between sclera and Tenon's capsule in intraocular neoplasm projection. Intraocular neoplasm localization and size is adjusted by applying transscleral diaphanoscopic examination method. 0.1-0.3 ml of photosensitizing gel based on viscoelastic of hyaluronic acid, selected from group containing chealon, viscoate or hyatulon, is transsclerally introduced into intraocular neoplasm structure using special purpose needle in dosed manner. The photosensitizing gel contains khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-1% by mass. Flexible polymer magnetolaser implant is extrasclerally introduced into the built tunnel in intraocular neoplasm projection zone under visual control using guidance beam. The implant has permanent ring-shaped magnet axially magnetized and producing permanent magnetic field of 3-4 mTesla units intensity, in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The implant is arranged with its north pole turned towards the intraocular neoplasm so that implant laser radiator lens is extrasclerally arranged in intraocular neoplasm projection zone. The implant light guide is sutured to sclera 5-6 mm far from the limb with single interrupted suture. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transscleral intraocular neoplasm laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm. The treatment course being over, the flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, neodymium-iron-boron or samarium-iron-nitrogen. 0.1-1% khlorin solution as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is additionally intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg and repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2 15-20 min later during 30-90 s.

EFFECT: complete destruction of neoplasm; excluded its further growth.

4 cl

FIELD: medicine.

SUBSTANCE: method involves applying transscleral diaphanoscopic examination method for adjusting intraocular neoplasm localization and size. Rectangular scleral pocket is built 2/3 times as large as sclera thickness which base is turned from the limb. Several electrodes manufactured from a metal of platinum group are introduced into intraocular neoplasm structure via the built scleral pocket. Next to it, intraocular neoplasm electrochemical destruction is carried out in changing electrodes polarity with current intensity of 100 mA during 1-10 min, and the electrodes are removed. Superficial scleral flap is returned to its place and fixed with interrupted sutures. 0.1-2% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transpupillary laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2. the operation is ended with placing sutures on conjunctiva. Platinum, iridium or rhodium are used as the metals of platinum group. The number of electrodes is equal to 4-8. 0.1-1% khlorin solution, selected from group containing photolon, radachlorine or photoditazine, is additionally repeatedly intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2.

EFFECT: complete destruction of neoplasm; excluded tumor recurrence; reduced risk of tumor cells dissemination.

3 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: the present innovation deals with treating vascular cutaneous neoplasms, such as nevus flammeus and gemangiomas. Light-thermal impact at energy ranged 39-47 J/sq. cm should be performed in two stages, and between them, 2-3 wk after the onset of vascular resistance at the first stage one should perform beta-therapy daily for 2-3 d at single dosage being 20 g. Then, 3 wk later it is necessary to conduct the second stage of light-thermal impact by starting at energy value being 42 J/sq. cm, not less. The method enables to shorten therapy terms due to applying combined method to affect vascular cutaneous neoplasms.

EFFECT: higher therapeutic and cosmetic effect.

1 ex

FIELD: medicine.

SUBSTANCE: method involves intravitreously introducing two electrodes into intraocular neoplasm after carrying out vitrectomy and retinotomy to expose the intraocular neoplasm. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with current intensity of 100 mA during 1-10 min or 10 mA during 10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2.The transformed retina and tumor destruction products are intravitreally removed. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. Another embodiment of the invention involves adjusting position and size of the intraocular neoplasm in trans-scleral diaphanoscopic way. Rectangular scleral pocket is built above the intraocular neoplasm to 2/3 of sclera thickness with its base turned away from limb. Several electrodes are introduced into intraocular neoplasm structure via the built bed. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with the same current intensity in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. Superficial scleral flat is returned to its place and fixed with interrupted sutures. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg after having carried out vitrectomy and retinotomy. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2. The transformed retina and tumor destruction products are intravitreally removed using vitreotome. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. The number of electrodes is equal to 4-8.

EFFECT: reduced risk of metastasizing.

4 cl, 13 dwg

FIELD: medicine.

SUBSTANCE: method involves building tunnel to posterior eyeball pole in inferoexterior and superexterior quadrants. The tunnel is used for implanting flexible polymer magnetolaser implant to the place, the subretinal neovascular membrane is localized. The implant has a permanent magnet shaped as a cut ring and is provided with drug delivery system and a short focus scattering lens of laser radiator connected to light guide. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 5-7 mTesla units intensity. It is arranged with its north pole turned towards sclera at the place of the subretinal neovascular membrane projection with extrascleral arrangement of laser radiator lens membrane being provided in the subretinal neovascular membrane projection area. The other implant end is sutured to sclera 5-6 mm far from the limb via holes made in advance. The implant is covered with conjunctiva and retention sutures are placed thereon. Light guide and drug supply system lead is attached to temple with any known method applied. Drugs are supplied via the implant drug supply system in retrobulbary way in any order. Triombrast is given in the amount of 0,4-0,6 ml and dexamethasone or dexone in the amount of 0,4-0,6 ml during 3-4 days every 12 h. 0.1-1% aqueous solution of khlorin is intravenously introduced at the third-fourth day after setting the implant as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, at a bolus dose of 0.8-1.1 mg/kg. Visual control of subretinal neovascular membrane cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the subretinal neovascular membrane with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at general dose of 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the subretinal neovascular membrane via laser light guide and implant lens, repeated laser irradiation of the subretinal neovascular membrane is carried out with radiation dose of 30-60 J/cm2.

EFFECT: accelerated subretinal edema and hemorrhages resorption; regression and obliteration of the subretinal neovascular membrane; prolonged vision function stabilization.

6 cl

FIELD: medicine.

SUBSTANCE: method involves filling vitreous cavity with perfluororganic compound. Two electrodes manufactured from platinum group metal are intravitreally, transretinally introduced into intraocular neoplasm. Electrochemical destruction is carried out with current intensity of 10-100 mA during 1-10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2 in perfluororganic compound medium. The transformed retina and tumor destruction products are intravitreally removed with perfluororganic compound volume being compensated with its additional introduction. Boundary-making endolasercoagulation of retinotomy area is carried out. The perfluororganic compound is substituted with silicon oil. The operation is ended in placing sutures over sclerotmy areas and over conjunctiva. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity. Platinum, iridium or rhodium are used as the platinum group metals.

EFFECT: complete destruction of neoplasm; reduced dissemination risk.

6 cl, 12 dwg

FIELD: medicine, applicable for stopping of pains of various nature.

SUBSTANCE: the device has a quantum-mechanical oscillator located in a casing, magnet, vessel for medicinal agent and a hollow cylinder. The magnet is installed between the oscillator and the vessel. Positioned in the vessel is a hollow cylinder having through holes on its surface.

EFFECT: quick and absolute anestesia.

2 ex, 1 dwg

FIELD: medicine.

SUBSTANCE: method involves administering laser radiation therapy once a day using low intensity pulsating radiation of wavelength equal to 890nmand power density of 0.03 mW/cm2. Injured organ projection to frontal abdominal wall is exposed to radiation at the first laser therapy stage in two fields acting upon each field for 2 min with radiation pulse succession frequency equal to 80 Hz in applying stable contact-type method. Total treatment dose on two fields is equal to 0.008 J/cm2. The second laser therapy stage begins immediately after having finished the first one in applying radiation along the large intestine path using labile contact-type method in a way that radiation pulse succession frequency equal to 80 Hz is applied first during 1 min and then frequencies of 600, 150 and 300 Hz are applied also during 1 min, respectively. Total treatment dose is equal to 0.032 J/cm2 at the second stage. Total treatment dose is equal to 0.04 J/cm2 at both stages.

EFFECT: enhanced effectiveness in inhibiting dysbacteriosis; reduced frequency of postoperative complications.

Up!